Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial
Diabetes Obesity and Metabolism2013Vol. 16(4), pp. 334–343
Citations Over TimeTop 10% of 2013 papers
Hans Denison, Catarina Nilsson, Lars Löfgren, Anders Himmelmänn, Gunnar Mårtensson, Mikael Knutsson, Ayman Al‐Shurbaji, Hans Törnqvist, Jan W. Eriksson
Abstract
Altered lipid handling and hormone secretion in the gut were demonstrated during 1-week treatment with the DGAT1 inhibitor AZD7687. However, the apparent lack of therapeutic window owing to GI side effects of AZD7687, particularly diarrhoea, makes the utility of DGAT1 inhibition as a novel treatment for diabetes and obesity questionable.
Related Papers
- → Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans(2002)227 cited
- → Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1(2004)104 cited
- → Effects of Postprandial Walking on Delayed Gastric Emptying and Intragastric Meal Distribution in Longstanding Diabetics(2000)19 cited
- → Blood Glucose Concentration Influences Postprandial Fullness in IDDM(1997)74 cited
- → Effects of postprandial walking on delayed gastric emptying and intragastric meal distribution in longstanding diabetics(2000)2 cited